Ironwood Pharmaceuticals Inc
IRWD- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001446847
No open-market purchases or sales by Ironwood Pharmaceuticals Inc insiders were filed in the last 90 days; 212 institutions reported holding it in 13F filings for Q2 2026, worth $675.8M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 8, 2026, 10:49 PM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 2, 2026 | Feb 27, 2025 | Jan 8, 2024 | Jan 9, 2023 | Jan 10, 2022 |
| Revenue | $296.2M | $351.4M | $442.7M | $410.6M | $413.8M |
| Research and development | $95.1M | $111.4M | $116.1M | $44.3M | $70.4M |
| Selling, general and administrative | $82.3M | $144.3M | $158.3M | $116.0M | $111.1M |
| Operating income | $98.5M | $93.1M | -$945.4M | $250.3M | $232.3M |
| Interest expense | – | – | $21.6M | $7.60M | $31.1M |
| Income tax | $46.0M | $64.3M | $83.5M | $77.4M | -$327.8M |
| Net income | $24.0M | $880.0K | -$1.00B | $175.1M | $528.4M |
| EPS, basic | $0.15 | $0.01 | $-6.45 | $1.13 | $3.26 |
| EPS, diluted | $0.15 | $0.01 | $-6.45 | $0.96 | $3.21 |
| Weighted shares, basic | 161.8M | 159.1M | 155.4M | 154.4M | 162.2M |
| Weighted shares, diluted | 163.0M | 160.1M | 155.4M | 186.3M | 164.4M |
| Margins and growth | |||||
| Operating margin | 33.3% | 26.5% | -213.5% | 61.0% | 56.1% |
| Net margin | 8.1% | 0.3% | -226.4% | 42.6% | 127.7% |
| Revenue growth, year over year | −15.7% | −20.6% | +7.8% | −0.8% | +6.2% |
| Net income growth, year over year | +2,629.2% | – | −672.5% | −66.9% | +397.7% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 2, 2026 | Feb 27, 2025 | Jan 8, 2024 | Jan 9, 2023 | Jan 10, 2022 |
| Cash and equivalents | $215.5M | $88.6M | $92.2M | $656.2M | $620.1M |
| Accounts receivable | $46.7M | $81.9M | $129.1M | $115.5M | $114.0M |
| Total current assets | $274.2M | $182.4M | $233.3M | $780.6M | $745.2M |
| Property, plant and equipment | $3.41M | $4.50M | $5.58M | $6.29M | $7.58M |
| Intangible assets | $2.04M | $2.86M | $3.68M | – | – |
| Total assets | $396.9M | $350.9M | $471.1M | $1.10B | $1.13B |
| Accounts payable | $2.90M | $2.13M | $7.83M | $483.0K | $935.0K |
| Total current liabilities | $242.2M | $38.8M | $276.1M | $25.5M | $161.7M |
| Long-term debt | – | – | – | $396.3M | $454.2M |
| Shareholders' equity | -$261.8M | -$301.3M | -$346.3M | $652.4M | $605.9M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 2, 2026 | Feb 27, 2025 | Jan 8, 2024 | Jan 9, 2023 | Jan 10, 2022 |
| Operating cash flow | $127.0M | $103.5M | $183.4M | $273.8M | $261.9M |
| Capital expenditures | $34.0K | $142.0K | $273.0K | $136.0K | $265.0K |
| Free cash flow | $127.0M | $103.4M | $183.2M | $273.6M | $261.6M |
| Depreciation and amortization | $1.10M | $1.20M | $1.20M | $1.40M | $1.50M |
| Stock-based compensation | $17.3M | $29.9M | $32.0M | $27.0M | $22.3M |
| Share buybacks | – | – | – | $126.4M | $24.1M |
| Investing cash flow | -$34.0K | -$142.0K | -$1.03B | -$136.0K | -$265.0K |
| Financing cash flow | $216.0K | -$107.0M | $277.2M | -$237.6M | -$4.55M |
| Net change in cash | $126.9M | -$3.60M | -$565.8M | $36.1M | $257.1M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 5.8% | 8.5% | 7.2% | 6.6% | 5.4% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 31, 2026 | 165.6M | +1.8% | SEC |
| Jul 31, 2026 | 165.2M | +1.7% | SEC |
| Apr 30, 2026 | 164.6M | +1.7% | SEC |
| Jan 31, 2026 | 163.1M | +0.8% | SEC |
| Oct 31, 2025 | 162.7M | +1.7% | SEC |
| Jul 31, 2025 | 162.4M | +1.7% | SEC |
| Apr 30, 2025 | 161.8M | +1.8% | SEC |
| Feb 28, 2025 | 161.8M | +3.4% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.